Preventing adverse drug events in hospital practice: an overview.

Preventing adverse drug events in hospital practice: an overview. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Preventing adverse drug events in hospital practice: an overview. Abstract Text:

Mirjam K Rommers,Irene M Teepe-Twiss,Henk-Jan Guchelaar,Mirjam K Rommers,Irene M Teepe-Twiss,Henk-Jan Guchelaar,

Adverse drug events (ADEs) are a considerable cause of morbidity and mortality in hospital practice. The precise frequency is unknown, but studies give an incidence number ranging from 2 until 52 ADEs per 100 patients. There are many different methods for definition, causality assessment, severity classification and detection which make it difficult to compare the different studies. A substantial part (in some studies up to 70%) of ADEs can be prevented and it is important to, besides their detection, focus on the prevention of these ADEs. In this literature review we give an overview of methods for preventing ADEs. There are many different tools with different impact on a particular part of the distribution system which has the potential to prevent ADEs. A multifaceted approach is needed. Two interesting strategies of prevention, pharmacist participation on ward rounds and computerised physician order entry with clinical decision support systems (CDSS), are highlighted. Moreover, two promising CDSS are discussed in more detail, namely computer-based monitoring systems and information systems which link laboratory and pharmacy data.

Preventing adverse drug events in hospital practice: an overview. Publishing Authors By Initials

MK Rommers,IM Teepe-Twiss,HJ Guchelaar,MK Rommers,IM Teepe-Twiss,HJ Guchelaar,

For similar pharmaceutical preparations research abstracts see: pharmaceutical preparations research

PUBMED ID PMID:

MEDLINE DATE:

Preventing adverse drug events in hospital practice: an overview. Journal Published:

PUBLICATION TYPE: Review

Journal: Pharmacoepidemiology and drug safety

VOLUME: 16

Page Numbers: 1129-35

Journal Abbreviation:

ISSN: 1053-8569

DAY: 29

MONTH: Oct

YEAR: 2007

Preventing adverse drug events in hospital practice: an overview. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9208369

Preventing adverse drug events in hospital practice: an overview. Keywords Mesh Terms:

KEYWORDS: Pharmaceutical Preparations

MESH TERMS: adverse effects

Chemical & Substance for Abstract: Preventing adverse drug events in hospital practice: an overview. Information

Substance Name: Pharmaceutical Preparations

Registry Number: 0

Grant and Affiliation Information for Preventing adverse drug events in hospital practice: an overview.

AFFILIATION: Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, The Netherlands. m.k.rommers@lumc.nl

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Pharmacoepidemiol Drug Saf

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Preventing adverse drug events in hospital practice: an overview Related Publications

• Comment on: The pharmacogenetics of methotrexate.
• Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients.
• GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
• Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.
• Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin?
• Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia.
• Pharmacogenetics of EGFR and VEGF inhibition.
• Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.
• Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype.
• Preventing adverse drug events in hospital practice: an overview.
• Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.
• UGT1A1(*)28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
• Use of plasmid-derived external quality control samples in pharmacogenetic testing.